Zylet Information
What's inside Zylet
Zylet Active Ingredients: loteprednol etabonate, tobramycin, details.| Zylet Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Zylet 0.5%-0.3% | suspension | ophthalmic | 100.0 milliliter(s) | OTC |
| Zylet 0.5%-0.3% | suspension | ophthalmic | 100.0 milliliter(s) | OTC |
Zylet in the News
Shift to Sub-2 mm Microincision Cataract Surgery Designed to Speed ... - Business Wire (press release)
As with other steroid/anti-infective ophthalmic combination drugs, Zylet is contraindicated in most viral diseases of the cornea and conjunctiva and also in ...
Fri Nov 09 08:04:38 -0500 2007
ISTA Provides Regulatory Update On T-Pred NDA Filing - Medical News Today (press release)
Tobrex and Tobradex are registered trademarks of Alcon Laboratories. Zylet is a registered trademark of Bausch & Lomb.
Sat May 05 00:03:56 -0400 2007
Ista: Eye Treatment Not Approved by FDA - Forbes
The agency did say T-Pred showed kill time equivalence versus products Zylet and Tobradex. Ista said it doesn't agree with this assessment.
Fri May 04 04:17:23 -0400 2007
Zylet Chemical Information
loteprednol etabonate - The etabonate salt form of loteprednol, an ophthalmic analog of the corticosteroid prednisolone with anti-inflammatory activity. Loteprednol etabonate exerts its effect by interacting with specific intracellular receptors and subsequently binds to DNA to modify gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Loteprednol etabonate specifically induces phospholipase A2 inhibitory proteins (collectively called lipocortins), which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes.
tobramycin - The sulfate salt form of tobramycin, an aminoglycoside antibiotic derived from Streptomyces tenebrarius with bacteriostatic activity. Following active transport into the cell, tobramycin binds irreversibly to a specific aminoglycoside receptor on the bacterial 30S ribosomal subunit and interferes with the initiation complex between messenger RNA and the 30S subunit, thereby inhibiting initiation of protein synthesis, consequently leading to bacterial cell death. In addition, tobramycin induces misreading of the mRNA template causing incorrect amino acids to be incorporated into the growing polypeptide chain, consequently interfering with protein elongation.
Zylet RSS Feed
